<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174391</url>
  </required_header>
  <id_info>
    <org_study_id>2019.046</org_study_id>
    <nct_id>NCT04174391</nct_id>
  </id_info>
  <brief_title>Lifestyles and Breast Cancer</brief_title>
  <acronym>LifeBreast</acronym>
  <official_title>Lifestyles for the Prevention of Relapses Among Women With Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: In Spain, 1 out of every 11 women will have a breast cancer before the age of 85
      years and breast cancer is the leading cause of potential years of life lost. The randomized
      intervention in PREDIMED trail, using Mediterranean diet with free provision of extra virgin
      olive oil (MedDiet+EVOO) dramatically and significantly reduced the occurrence of cases of
      postmenopausal breast cancer.

      Objectives: Assess the efficacy of a nutritional intervention with MedDiet+EVOO for the
      prevention of relapses among women with early breast cancer.

      Methods: Randomized, multicenter trial (LifeBreast) among 766 women diagnosed with early
      breast cancer. Participants will be randomized in a 1:1 ratio to i) MedDiet+EVOO or ii)
      low-fat diet. Changes in circulating tumor cells, inflammatory biomarkers, oxidative stress
      and quality of life will be evaluated. The intervention will be delivered by face-to-face
      interviews with study dietitian, phone calls, and online tools. Participants in the
      MedDiet+EVOO group will receive 0.5l/week of EVOO and participants in the low-fat group will
      receive allotments of different foods, both at no cost. Generalized estimating equations will
      be used to estimate between-group differences in the following outcomes: circulating tumor
      cells, inflammatory biomarkers, oxidative stress, and quality of life will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of circulating tumour cells</measure>
    <time_frame>average follow-up: 1.5 years</time_frame>
    <description>Blood samples will be collected at baseline and yearly thereafter. Presence of circulating tumour cells will be determined with immunohistochemical techniques and defined as ≥1 circulating tumour cell in 10 ml of peripheral blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in inflammatory markers</measure>
    <time_frame>average follow-up: 1.5 years</time_frame>
    <description>Changes in the inflammatory profile of the participants as plasma cytokines — such as IL-6 —, changes in oxidative stress response with the lipid peroxidation test (LPO test), and changes in DNA damage with electrophoresis single-cell alkaline (comet Assay) in buffy coat will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>average follow-up: 1.5 years</time_frame>
    <description>Changes in quality of life will be assessed with the 36-Item Short Form Survey (SF-36) questionnaire. The questionnaire score ranges from 0-100, with higher score meaning better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>average follow-up: 1.5 years</time_frame>
    <description>Changes in quality of life will be assessed with the the Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire. The questionnaire score ranges from 0-148, with higher score meaning better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body mass-index</measure>
    <time_frame>average follow-up: 1.5 years</time_frame>
    <description>Weight and height will be ascertained at baseline and yearly thereafter Weight and height will be directly measured in triplicate by trained study personnel</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in lipid profile</measure>
    <time_frame>average follow-up: 1.5 years</time_frame>
    <description>Blood samples will be collected at baseline and yearly thereafter. Blood samples will be obtained after an overnight fast to determine levels of cholesterol using standard enzymatic methods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in lipid profile</measure>
    <time_frame>average follow-up: 1.5 years</time_frame>
    <description>Blood samples will be collected at baseline and yearly thereafter. Blood samples will be obtained after an overnight fast to determine levels of triglycerides using standard enzymatic methods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood glucose</measure>
    <time_frame>average follow-up: 1.5 years</time_frame>
    <description>Blood samples will be collected at baseline and yearly thereafter. Blood samples will be obtained after an overnight fast to determine levels of fasting blood glucose using standard enzymatic methods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in mammographic density</measure>
    <time_frame>average follow-up: 1.5 years</time_frame>
    <description>All available digital mammograms during follow-up of the contralateral non-affected breast of each woman will be collected, they will be read by an experienced radiologist in a blind way (without knowing the allocation group) using the DM-Scan program.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">766</enrollment>
  <condition>Malignant Tumor of Breast</condition>
  <arm_group>
    <arm_group_label>Mediterranean diet supplemented with extra-virgin olive oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-fat diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mediterranean diet supplemented with extra-virgin olive oil</intervention_name>
    <description>Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.</description>
    <arm_group_label>Mediterranean diet supplemented with extra-virgin olive oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low-fat diet</intervention_name>
    <description>Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods — equivalent to the extra-virgin olive oil allotment — will be received by participants of this group for free. In addition, advice on physical activity will be provided.</description>
    <arm_group_label>Low-fat diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women with primary pathologically confirmed invasive breast adenocarcinoma in stages I, II
        or IIIA

        Exclusion Criteria:

          -  breast cancer recurrence

          -  in situ CDIS or LDIS

          -  inability or unwillingness to give written informed consent

          -  difficulty to comply with the intervention

          -  lack of willpower to change their diet (using the models of Prochaska and DiClemente)

          -  inability or unwillingness to communicate with study personnel

          -  medical condition that prevents the intervention (digestive disease with fat
             intolerance; severe psychiatric, neurological or endocrine disease; or allergy or
             hypersensitivity to any of the key foods of the intervention (EVOO or nuts) or
             impossibility to follow a Mediterranean diet and/or EVOO intake

          -  immunodeficiency or HIV-positive status

          -  concomitant condition that limits life-expectancy to less than 1 year

          -  difficulty or impossibility for an adequate follow-up

          -  institutionalized patients with lack of autonomy

          -  impossibility for attending group sessions and yearly follow-up visits or for
             telephone contact

          -  usual alcohol consumption &gt;80 g/d

          -  BMI&gt;40

          -  Patients with acute infection or inflammatory process (e.g. pneumonia) may be included
             in the study three months after the resolution of the infectious symptoms
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Estefania A Toledo, MD, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Navarra (IdiSNA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trinidad Dierssen-Sotos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cantabria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose J Jimenez-Moleon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigación Biosanitaria de Granada ibs.GRANADA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Pollan, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Salud Carlos III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Estefania A Toledo, MD, MPH, PhD</last_name>
    <phone>+34 948425600</phone>
    <phone_ext>806224</phone_ext>
    <email>etoledo@unav.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel A Martinez-Gonzalez, MD, MPH, PhD</last_name>
    <phone>+34 948425600</phone>
    <phone_ext>806463</phone_ext>
    <email>mamartinez@unav.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cantabria</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Trinidad Dierssen-Sotos, MD,PhD</last_name>
      <email>trinidad.dierssen@unican.es</email>
    </contact>
    <investigator>
      <last_name>Trinidad Dierssen-Sotos, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Llorca, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ines Gomez-Acebo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Navarra-Instituto de Investigación Sanitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miguel A Martinez-Gonzalez, MD,MPH,PhD</last_name>
      <phone>+34 94835600</phone>
      <phone_ext>806463</phone_ext>
      <email>mamartinez@unav.es</email>
    </contact>
    <investigator>
      <last_name>Estefania A Toledo, MD,MPH,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel A Martinez-Gonzalez, MD,MPH,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose M Aramendía-Beitia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cesar I Fernandez-Lazaro, MPH,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Romanos-Nanclares, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigación Biosanitaria de Granada ibs.GRANADA</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose J Jimenez-Moleon, MD, PhD</last_name>
      <email>jjmoleon@ugr.es</email>
    </contact>
    <investigator>
      <last_name>Jose J Jimenez-Moleon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocio Barrios, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Torne-Poyatos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Mozas-Moreno, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Amezcua-Prieto, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inmaculada Salcedo-Bellido, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocio Olmedo-Requena, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Jaen</name>
      <address>
        <city>Jaen</city>
        <zip>23071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose J Gaforio, MD, PhD</last_name>
      <email>jgaforio@ujaen.es</email>
    </contact>
    <investigator>
      <last_name>Jose J Gaforio, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Sanchez-Quesada</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Navarra</investigator_affiliation>
    <investigator_full_name>Estefania Toledo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer prognosis</keyword>
  <keyword>Mediterranean diet</keyword>
  <keyword>extra-virgin olive oil</keyword>
  <keyword>low-fat diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

